Gabapentin
Product Images NDC 33358-154

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 33358-154). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rxchange Co., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin (Gabapentin)

Gabapentin is a medication that comes in the form of 600mg tablets. It is manufactured by InvaGen Pharmaceuticals and can be identified using the lot# and NDC code. The tablets are dispensed in a light-resistant container and should be stored at controlled room temperature. Each tablet is debossed with a "1" on the left side and "bisect on the other." The text includes information about the manufacturer, lot#, and expiration date, but no information about the medication's uses or side effects.*

FDA Label Image

D:\work\elabel\2012.10\10.25\1\figure_01.jpg (C13551d6 Figure 01)

FDA Label Image

D:\work\elabel\2012.10\10.25\1\gabapentin_25-oct-2012\figure_02.jpg (C13551d6 Figure 02)

This is a graph with the title "Weekly Mean Pain Scores" on the Y-axis and "Weeks" on the X-axis. The graph was generated from Study 1, and it shows the observed cases in the ITT (intent-to-treat) population. The medication in question is Gabapentin, and the dose administered was 3500 mg daily. The other text seems to be a mix of random characters and symbols that do not provide any useful information.*

FDA Label Image

D:\work\elabel\2012.10\10.25\1\gabapentin_25-oct-2012\figure_03.jpg (C13551d6 Figure 03)

This is a table with information related to pain scores obtained from a study. There were two treatments: "Placebo" and "Gabapentin" at two different doses - 1800 and 2400 mg/day. The table shows the mean pain scores at baseline and during 7 weeks of observation. The figure indicates a line graph of the weekly average pain scores during the study.*

FDA Label Image

D:\work\elabel\2012.10\10.25\1\gabapentin_25-oct-2012\figure_04.jpg (C13551d6 Figure 04)

FDA Label Image

D:\work\elabel\2012.10\10.25\1\gabapentin_25-oct-2012\figure_05.jpg (C13551d6 Figure 05)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.